{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-007945","form_type":"8-K","ticker":"INFU","cik":"0001337013","company_name":"InfuSystem Holdings, Inc","filed_at":"2023-03-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.532550+00:00","generated_at":"2026-06-18T01:46:07.423177+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"InfuSystem FY2022 revenue up 7% to record $109.9M, but adjusted EBITDA down 14%","bullets":["Full year net revenue $109.9M (+7% YoY); Q4 revenue $28.8M (+9% YoY).","Adjusted EBITDA $20.7M FY2022, down 14% YoY; Q4 adj. EBITDA $5.5M, down 16%.","Net income for year less than $0.1M; Q4 diluted EPS $0.01.","Guides FY2023 revenue growth 8-10% (~$118-121M); adj. EBITDA margin >19%.","Launched wound care JV with Sanara Medtech; biomedical services contract ramp-up continues."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-007945","json":"https://secwatch.observer/filing/0001628280-23-007945.json","markdown":"https://secwatch.observer/filing/0001628280-23-007945.md","text":"https://secwatch.observer/filing/0001628280-23-007945.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1337013/000162828023007945/0001628280-23-007945-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1337013/000162828023007945/infu-20230315.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T01:46:07.423177+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"661f59e36dd0b279f30f71e615df2270a6e04701","claim":"InfuSystem Holdings, Inc reported fourth quarter and full year ended December 31, 2022 results: revenue Net revenues totaled $109.9 million, net income Net income of less than $0.1 million, EPS $0.01 per diluted share. Guidance reaffirmed.","evidence_excerpt":"InfuSystem Announces Operational and Financial Results for Fourth Quarter and Full Year 2022 Full Year 2022 vs. Full Year 2021: Record Net Revenues: $109.9 million, a 7% increase","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1337013/000162828023007945/0001628280-23-007945-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2022"},{"label":"Revenue","value":"Net revenues totaled $109.9 million"},{"label":"Net income","value":"Net income of less than $0.1 million"},{"label":"EPS","value":"$0.01 per diluted share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}